These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 2540356)

  • 1. [In vitro activity of fluconazole, a novel bistriazole antifungal agent].
    Yamaguchi H; Uchida K; Kawasaki K; Matsunaga T
    Jpn J Antibiot; 1989 Jan; 42(1):1-16. PubMed ID: 2540356
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [In vivo and in vitro antifungal activity of fluconazole].
    Kawasaki K; Matsumura Y; Ogawa M; Tsuji A; Matsunaga T; Goto S
    Jpn J Antibiot; 1991 May; 44(5):552-61. PubMed ID: 1880935
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [In vitro antifungal activity of itraconazole, a new triazole antifungal agent, against clinical isolates from patients with systemic mycoses].
    Uchida K; Matsuzaka A; Aoki K; Yamaguchi H
    Jpn J Antibiot; 1991 May; 44(5):562-70. PubMed ID: 1652654
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antifungal activity of D0870 against murine infections and its mechanism of action.
    Yamada H; Tsuda T; Watanabe T; Kusakabe S; Mochizuki H
    Chemotherapy; 1998; 44(2):112-20. PubMed ID: 9551242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro and in vivo antifungal activities of ER-30346, a novel oral triazole with a broad antifungal spectrum.
    Hata K; Kimura J; Miki H; Toyosawa T; Nakamura T; Katsu K
    Antimicrob Agents Chemother; 1996 Oct; 40(10):2237-42. PubMed ID: 8891121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro and in vivo antifungal activities of FX0685, a novel triazole antifungal agent with potent activity against fluconazole-resistant Candida albicans.
    Takahata S; Okutomi T; Ohtsuka K; Hoshiko S; Uchida K; Yamaguchi H
    Med Mycol; 2005 May; 43(3):227-33. PubMed ID: 16010849
    [TBL] [Abstract][Full Text] [Related]  

  • 7. T-8581, a new orally and parenterally active triazole antifungal agent: in vitro and in vivo evaluations.
    Yotsuji A; Shimizu K; Araki H; Fujimaki K; Nishida N; Hori R; Annen N; Yamamoto S; Hayakawa H; Imaizumi H; Watanbe Y; Narita H
    Antimicrob Agents Chemother; 1997 Jan; 41(1):30-4. PubMed ID: 8980750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Candida and candidaemia. Susceptibility and epidemiology.
    Arendrup MC
    Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activity of fluconazole (UK 49,858) and ketoconazole against Candida albicans in vitro and in vivo.
    Rogers TE; Galgiani JN
    Antimicrob Agents Chemother; 1986 Sep; 30(3):418-22. PubMed ID: 3022641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [In vitro susceptibility to fluconazole of fungal strains freshly isolated from child patients with deep-seated mycoses].
    Yamaguchi H; Uchida K
    Jpn J Antibiot; 1993 Aug; 46(8):647-53. PubMed ID: 8230734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro and in vivo antifungal activities of D0870, a new triazole agent.
    Yamada H; Tsuda T; Watanabe T; Ohashi M; Murakami K; Mochizuki H
    Antimicrob Agents Chemother; 1993 Nov; 37(11):2412-7. PubMed ID: 8285626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Synthesis and antifungal activity of 1-(1H-1,2,4-triazole-1-yl)-2-(2,4-difluorophenyl)-3-substituted-2-propanols].
    Zhang DZ; Zhou TS; Wu YJ; Liu CM; Ma MC; Feng XT
    Yao Xue Xue Bao; 1997 Dec; 32(12):943-9. PubMed ID: 11596195
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [In vitro antifungal activity of itraconazole: a comparative study with ketoconazole].
    Hiratani T; Yamaguchi H
    Jpn J Antibiot; 1991 May; 44(5):580-7. PubMed ID: 1652656
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Susceptibility of fungi isolated from clinical materials to voriconazole].
    Pawlik B; Szul A; Macura AB
    Med Dosw Mikrobiol; 2006; 58(2):155-61. PubMed ID: 17133909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of culture media on the in vitro susceptibility of selected opportunistic fungi to fluconazole and itraconazole.
    Sekhon AS; Padhye AA; Garg AK; Hamir Z
    Chemotherapy; 1992; 38(3):169-73. PubMed ID: 1324830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of the new triazole, voriconazole (UK-109,496), on the interactions of Candida albicans and Candida krusei with endothelial cells.
    Fratti RA; Belanger PH; Sanati H; Ghannoum MA
    J Chemother; 1998 Feb; 10(1):7-16. PubMed ID: 9531069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antifungal effects of fluconazole (UK 49858), a new triazole antifungal, in vitro.
    Odds FC; Cheesman SL; Abbott AB
    J Antimicrob Chemother; 1986 Oct; 18(4):473-8. PubMed ID: 3021710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts.
    Sabatelli F; Patel R; Mann PA; Mendrick CA; Norris CC; Hare R; Loebenberg D; Black TA; McNicholas PM
    Antimicrob Agents Chemother; 2006 Jun; 50(6):2009-15. PubMed ID: 16723559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of culture media on in vitro susceptibility testing of fluconazole against some yeasts.
    Sekhon AS; Garg AK; Hamir Z
    Mycoses; 1991; 34(7-8):319-22. PubMed ID: 1803235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Growth inhibitory action of ebselen on fluconazole-resistant Candida albicans: role of the plasma membrane H+-ATPase.
    Billack B; Santoro M; Lau-Cam C
    Microb Drug Resist; 2009 Jun; 15(2):77-83. PubMed ID: 19432523
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.